Venture capital: what’s different today from 2000?

Join Streamly for free to watch more
Venture capital: what’s different today from 2000?

Venture capital: what’s different today from 2000?

About the speakers
  • Thomas Kristensen
    Thomas Kristensen
    Partner at LGT Capital Partners
    Thomas Kristensen, Partner at LGT Capital Partners Ltd. Mr. Kristensen joined LGT Capital Partners in 2004 and heads the firms venture capital strategy. Prior to joining LGT Capital Partners Mr. Kristensen worked for investment bank Lazard in London. Mr. Kristensen holds an MSc in Finance from Cass Business School in London, and a BSc in Economics from the University of Copenhagen.
  •  Thomas Schneider
    Thomas Schneider
    Partner at Isomer Capital
    Partner at Isomer Capital, backing European VC champions and their breakout companies. Focusing on building long-lasting partnerships with GPs and LPs.
  • Catherine Lewis La Torre
    Catherine Lewis La Torre
    CEO at British Patient Capital
    Catherine was appointed CEO of British Patient Capital, a commercial subsidiary of the British Business Bank (BBB), in October 2022. She joined BBB in 2016 to lead its commercial subsidiary British Business Investments, and has also served as BBB’s interim CEO. Prior to 2016, she was Head of Private Equity for Cardano Risk Management, managing a global portfolio of private capital investments on behalf of UK pension funds. She was previously a Partner and Managing Director of Paris-based European private equity firm, Fondinvest Capital, and before that a founding partner of Nordic Private Equity funds manager, Proventure. Catherine also established a consultancy business advising sovereign wealth funds and institutional investors in Asia, the Middle East and the US on their European private capital strategies. Catherine is a member of the Rose Review Board.
  • Hussein Kanji
    Hussein Kanji
    Partner at Hoxton Ventures
    Hussein is a partner at Hoxton Ventures. He currently represents Hoxton on the boards of Baseimmune, BeyondRisk, Biocortex, Biotx, DruidAI, Finesse, Fy!, Giraffe360, Kbox, Kitt, Luminary, Peptone, PillSorted, Raptor Supplies, Really Clever, Rensair, Replai, Replan, Skin Analytics, TourRadar and XYZ Reality, and serves as a board observer on Behavox, Karakuri, Panakeia and Vidya Health. He previously served on the boards of Babylon Health (NYSE:BBLN), bd4travel (acquired by Dnata), Campanja (acquired by 24/7 Media), Darktrace (LSE:DARK), Deliveroo (LSE:ROO), SOCOS (acquired by Sophos) and Yieldify (acquired by Publicis). Hussein serves on the board of Tech Nation, a UK quasi non-governmental organization, and UCLB, the commercialization company of UCL. He also sits on the advisory board of GTO Partners, a tech mid-market buyout firm, and Landscape, a venture capital review site. In a personal capacity, he is an angel investor in Apex:E3, Builder.ai, Callaly, GoCardless, Mellizyme, MyGlamm, Reachdesk and Signpost. While forming Hoxton, he helped Eros STX Global develop ErosNow, an online streaming video platform for Bollywood. Prior to Hoxton, Hussein was an associate with Accel Partners. He joined Accel from Microsoft Corporation. Earlier in his career, he worked with three startups, Safe-View (acquired by L-3), Radiance Technologies (acquired by Comcast) and Studio Verso (acquired by KPMG). Hussein holds an MBA from London Business School and did his undergraduate studies in Symbolic Systems at Stanford University. He stubbornly refuses to swear allegiance to a monarch and remains a proud American.

Key takeaways